Filing Details

Accession Number:
0001479290-19-000020
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-02-20 21:31:33
Reporting Period:
2019-02-15
Accepted Time:
2019-02-20 21:31:33
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1479290 Revance Therapeutics Inc. RVNC Pharmaceutical Preparations (2834) 770551645
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1597583 Daniel L Browne C/O Revance Therapeutics, Inc.
7555 Gateway Boulevard
Newark CA 94560
Ceo And President Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2019-02-15 3,154 $17.69 174,389 No 4 F Direct
Common Stock Disposition 2019-02-19 5,446 $17.68 168,943 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 F Direct
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 409 Indirect See footnote
Footnotes
  1. Represents the number of shares withheld by and surrendered to the issuer on February 15, 2019, to satisfy tax withholding obligations that arose in connection with the vesting of a 2017 Restricted Stock Award (the "RSA") for 25,800 shares. The RSA vests in three equal annual installments from February 15, 2017, subject to Mr. Browne's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.
  2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mr. Browne.
  3. These shares are held by the Dan and Brenda Browne Living Trust. Mr. Browne is a Trustee of the Dan and Brenda Browne Living Trust.